Edgewise Therapeutics reported Q4 FY2025 results, ending the quarter with cash, cash equivalents and marketable securities of approximately USD 530.1 million (as of Dec. 31, 2025). R&D expenses were USD 43.6 million in Q4, while G&A expenses were USD 12.4 million. Net loss for Q4 was USD 50.2 million, or USD 0.47 per share. On the pipeline, Edgewise said 12-week Part D data from its CIRRUS-HCM Phase 2 trial of EDG-7500 in obstructive and nonobstructive hypertrophic cardiomyopathy are expected in H1 2026, with a Phase 3 initiation planned in H2 2026. The company also expects top-line Phase 1 healthy adult data for EDG-15400 in H1 2026 and plans to start a Phase 2 trial in heart failure with preserved ejection fraction in H2 2026. For sevasemten in Becker muscular dystrophy, Edgewise reiterated that pivotal GRAND CANYON top-line data are expected in Q4 2026, with an NDA submission planned for H1 2027, and said 99% of eligible participants had enrolled in the MESA open-label extension as of Dec. 2025, with up to four years of exposure.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Edgewise Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-020108), on February 26, 2026, and is solely responsible for the information contained therein.